Skip to main content

Table 3 Type and genomic location of ESR1 alterations detected in FFPE samples

From: ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy

 

n (%)

Total number of ESR1 alterations

25 (100)

Point mutations

22 (88.0)

 p.T140K, c.419C > A (E3)

1 (4.5)

 p.E380Q, c.1138G > C (E7)

1 (4.5)

 p.L536P, c.1607 T > C (E10)

1 (4.5)

 p.Y537N, c.1609 T > A (E10)

2 (9.0)

 p.Y537S, c.1610A > C (E10)

6 (27.2)

 p.Y537C, c.1610A > G (E10)

1 (4.5)

 p.D538G, c.1613A > G (E10)

10 (45.5)

Indels

 V422del (E8)

1 (4.0)

Rearrangements

ESR1-CCDC170 (E2-E10)

1 (4.0)

Amplifications

 CNV 5.98

1 (4.0)